Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma
- PMID: 29921698
- DOI: 10.1158/0008-5472.CAN-17-3714
Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma
Abstract
The immunosuppressive microenvironment in glioblastoma (GBM) prevents an efficient antitumoral immune response and enables tumor formation and growth. Although an understanding of the nature of immunosuppression is still largely lacking, it is important for successful cancer treatment through immune system modulation. To gain insight into immunosuppression in GBM, we performed a computational analysis to model relative immune cell content and type of immune response in each GBM tumor sample from The Cancer Genome Atlas RNA-seq data set. We uncovered high variability in immune system-related responses and in the composition of the microenvironment across the cohort, suggesting immunologic diversity. Immune cell compositions were associated with typical alterations such as IDH mutation or inactivating NF1 mutation/deletion. Furthermore, our analysis identified three GBM subgroups presenting different adaptive immune responses: negative, humoral, and cellular-like. These subgroups were linked to transcriptional GBM subtypes and typical genetic alterations. All G-CIMP and IDH-mutated samples were in the negative group, which was also enriched by cases with focal amplification of CDK4 and MARCH9. IDH1-mutated samples showed lower expression and higher DNA methylation of MHC-I-type HLA genes. Overall, our analysis reveals heterogeneity in the immune microenvironment of GBM and identifies new markers for immunosuppression. Characterization of diverse immune responses will facilitate patient stratification and improve personalized immunotherapy in the future.Significance: This study utilizes a computational approach to characterize the immune environments in glioblastoma and shows that glioblastoma immune microenvironments can be classified into three major subgroups, which are linked to typical glioblastoma alterations such as IDH mutation, NF1 inactivation, and CDK4-MARCH9 locus amplification.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/19/5574/F1.large.jpg Cancer Res; 78(19); 5574-85. ©2018 AACR.
©2018 American Association for Cancer Research.
Similar articles
-
Analysis of immunobiologic markers in primary and recurrent glioblastoma.J Neurooncol. 2018 Apr;137(2):249-257. doi: 10.1007/s11060-017-2732-1. Epub 2018 Jan 4. J Neurooncol. 2018. PMID: 29302887 Free PMC article.
-
Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.Cancer Med. 2019 Jun;8(6):2897-2907. doi: 10.1002/cam4.2192. Epub 2019 Apr 30. Cancer Med. 2019. PMID: 31038851 Free PMC article.
-
IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.Acta Neuropathol Commun. 2021 Dec 24;9(1):200. doi: 10.1186/s40478-021-01304-5. Acta Neuropathol Commun. 2021. PMID: 34952640 Free PMC article.
-
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.Front Immunol. 2024 Sep 13;15:1424396. doi: 10.3389/fimmu.2024.1424396. eCollection 2024. Front Immunol. 2024. PMID: 39346924 Free PMC article. Review.
-
Immune Microenvironment in Glioblastoma Subtypes.Front Immunol. 2018 May 8;9:1004. doi: 10.3389/fimmu.2018.01004. eCollection 2018. Front Immunol. 2018. PMID: 29867979 Free PMC article. Review.
Cited by
-
Metabolic Rewiring in Adult-Type Diffuse Gliomas.Int J Mol Sci. 2023 Apr 16;24(8):7348. doi: 10.3390/ijms24087348. Int J Mol Sci. 2023. PMID: 37108511 Free PMC article. Review.
-
RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target.Int J Mol Sci. 2025 Jun 10;26(12):5555. doi: 10.3390/ijms26125555. Int J Mol Sci. 2025. PMID: 40565018 Free PMC article.
-
Investigating the Prognostic and Oncogenic Roles of Membrane-Associated Ring-CH-Type Finger 9 in Colorectal Cancer.Genet Res (Camb). 2024 Aug 17;2024:9279653. doi: 10.1155/2024/9279653. eCollection 2024. Genet Res (Camb). 2024. PMID: 39185021 Free PMC article.
-
Nanomaterials: A powerful tool for tumor immunotherapy.Front Immunol. 2022 Aug 22;13:979469. doi: 10.3389/fimmu.2022.979469. eCollection 2022. Front Immunol. 2022. PMID: 36072591 Free PMC article. Review.
-
Development and validation of a pyroptosis-related genes signature for risk stratification in gliomas.Front Genet. 2023 Feb 13;14:1087563. doi: 10.3389/fgene.2023.1087563. eCollection 2023. Front Genet. 2023. PMID: 36861130 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous